Digital Pathology Expansion Acupath has recently integrated with Artera to enable seamless sending of biopsy slide images and expects results within 24 hours, indicating a strong push toward faster data workflow and digital collaboration with partners.

US Digital Scanning Adoption Partnership with Azer Scientific to deploy the first AzerView Digital Pathology scanner in the United States signals a growing appetite for advanced scanning and digital pathology capabilities that can be cross-sold to existing clients.

New Testing Portfolios Launches in 2023 of BioFire GI Panel and ongoing URO17 biomarker work position Acupath as a provider of specialized molecular and multiplex testing, offering opportunities to upsell to hospitals seeking comprehensive panel diagnostics.

Strategic Collaborations Multiple alliances with technology and service partners (Lumea, AIRA Matrix, Test Today) show a pattern of expanding capability through ecosystem partnerships, presenting avenues to jointly market broader solutions to current and prospective clients.

Scale and Reach With over 500 active clients and 150,000+ annual specimens served, Acupath already demonstrates broad market reach; the sales segment can target mid-to-large clinical groups seeking sub-specialized pathology and rapid turnaround capabilities.